

Northwestern University Institutional Biosafety Committee

Meeting Minutes

Date: 6/18/2025 11:00 AM

Called to Order: 11:00 AM

Adjourned: 1:00 PM

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference (either Zoom or Microsoft Teams, as Northwestern policy requires). A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

IBC Members

Please see the NIH Office of Science Policy Registration Management System for official Committee Members' roles.

Name	Committee Role	Attendance
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	-
Jacob Class	Member	Present
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	-
Robert Foreman	Member	Present
Susan Fox	Member	Present
Lucy Godley	Member	Present
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	Present
Sarah Kopp	Member	Present
Maciej Lesniak	Member	-
Stephen Levin	Member	Present
Liming Li	Member	Present
Emma Liechty	Member	Present
Narsa Machireddy	Member	-
Michael McRaven	Member	Present
Jeremy T Ritzert	Member	Present
Irina Shepotinovskaya	Member	-
Suchitra Swaminathan	Member	-
Clyde Yancy	Member	-
Nicolette Zielinski-Mozny	Member	Present
Robert Birkett	Alternate	Present

Name	Committee Role	Attendance
Crista Brawley	Alternate	-
Jane Cullen	Alternate	-
Mandy Kozlowski	Alternate	Present
Alicia McLuckie	Alternate	-
Marina Zelivyanskaya	Alternate	Present
James Zewe	Alternate	-
Michael Hantak	Administrator	Present
Iwona Spath	Administrator	Present

Registrations for Full-Committee Review

Research Group	Principal Investigator	Submission Type
Amendment for BIO20220035	Atique Ahmed	Amendment
Bachta Lab	Kelly Bachta	Initial Protocol
Amendment for BIO20240082	Xiaomin Bao	Amendment
Battle Lab	Daniel Battle	Initial Protocol
Garcia-Anoveros Lab	Jaime Garcia-Anoveros	Initial Protocol
Hamvas Lab	Aaron Hamvas	Initial Protocol
Amendment for BIO20230052	Karen Ho	Amendment
Holmgren Lab	Robert Holmgren	Initial Protocol
Hope Lab	Thomas Hope	De Novo Review
MacIver Lab	Malcolm MacIver	Initial Protocol
Martina Lab	Marco Martina	Initial Protocol
Servin-Vences Lab	Rocio Servin-Vences	Initial Protocol
Singer Lab	Benjamin Singer	Initial Protocol
Snead Lab	Wilton Snead	Initial Protocol
Thumbikat Lab	Praveen Thumbikat	Initial Protocol
Vaughan Lab	Douglas Vaughan	De Novo Review

Approval of Previous Meeting Minutes

Previous Meeting Date: 5/21/25

Determination: Approve

Comments: Smith made a motion to approve the minutes. Hummel seconded the motion. The Committee unanimously supported the motion.

Meeting Minutes

Review of Amendment for BIO20220035

Amendment

Principal Investigator	Atique Ahmed
Submission ID	BIO20220035-AM0001
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-F-8-C-I• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2+
Determination	Approve with minor
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission with minor modifications.</p> <p>The Committee unanimously supported the motion.</p>

Review of Bachta Lab

Initial Protocol

Principal Investigator	Kelly Bachta
Submission ID	BIO20250053
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F-2• Section III-D-4-b• Section III-D-4• Section III-F-7• Section III-F• Section III-E• Section III-F-1• Section III-D-2• Section III-D• Section III-F-8• Section III-F-6
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Amendment for BIO20240082

Amendment

Principal Investigator	Xiaomin Bao
Submission ID	BIO20240082-AM0001
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2+
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Batlle Lab

Initial Protocol

Principal Investigator	Daniel Batlle
Submission ID	BIO20250046
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F-2• Section III-E-3• Section III-F-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-F-8-C-VII• Section III-D• Section III-F-8-C-VIII
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Garcia-Anoveros Lab

Initial Protocol

Principal Investigator	Jaime Garcia-Anoveros
Submission ID	BIO20240150
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F-2• Section III-E-3• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Hamvas Lab

Initial Protocol

Principal Investigator	Aaron Hamvas
Submission ID	BIO20250054
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F• Section III-F-1
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Amendment for BIO20230052

Amendment

Principal Investigator	Karen Ho
Submission ID	BIO20230052-AM0001
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-F• Section III-E• Section III-F-1• Section III-F-8-C-VII• Section III-F-8-C-VIII
Containment Level	BSL-2
Determination	Approve with modifications
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission with minor modifications.</p> <p>The Committee unanimously supported the motion.</p>

Review of Holmgren Lab

Initial Protocol

Principal Investigator	Robert Holmgren
Submission ID	BIO20250047
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F-2• Section III-D-4• Section III-F• Section III-F-8-C-II• Section III-F-1• Section III-E-2-b-(5)• Section III-D
Containment Level	BSL-1
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p> <p>Holmgren recused.</p>

Review of Hope Lab

De Novo Review

Principal Investigator	Thomas Hope
Submission ID	BIO20250038
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-D-1-a• Section III-F-2• Section III-D-1-b• Section III-D-4• Section III-F• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-3
Determination	Approve with modifications
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission with minor modifications.</p> <p>The Committee unanimously supported the motion.</p> <p>McRaven recused.</p>

Review of MacIver Lab

Initial Protocol

Principal Investigator	Malcolm MacIver
Submission ID	BIO20240155
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Martina Lab

Initial Protocol

Principal Investigator	Marco Martina
Submission ID	BIO20250061
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-E-3-a• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Servin-Vences Lab

Initial Protocol

Principal Investigator	Rocio Servin-Vences
Submission ID	BIO20250059
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4-b• Section III-D-4• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-F-8
Containment Level	BSL-2
Determination	Defer
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to defer this submission.</p> <p>The Committee unanimously supported the motion.</p>
Associated IACUC Studies	IS00031456
Associated IRB Studies	N/A
Supporting Documents	None

Review of Singer Lab

Initial Protocol

Principal Investigator	Benjamin Singer
Submission ID	BIO20250055
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Snead Lab

Initial Protocol

Principal Investigator	Wilton Snead
Submission ID	BIO20250074
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F-2• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2+
Determination	Approve with modifications
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission with minor modifications.</p> <p>The Committee unanimously supported the motion.</p>

Review of Thumbikat Lab

Initial Protocol

Principal Investigator	Praveen Thumbikat
Submission ID	BIO20240176
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-F-2• Section III-E-3• Section III-F• Section III-E• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Review of Vaughan Lab

De Novo Review

Principal Investigator	Douglas Vaughan
Submission ID	BIO20250073
Applicable NIH Guidelines	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-D-4-c-(1)• Section III-F-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-F-8-C-VIII
Containment Level	BSL-2
Determination	Approve
Comments	<p>The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.</p> <p>Training for the PI and all applicable lab personnel was current at the time the submission was approved.</p> <p>Research Safety has conducted a facility inspection within the last year and has determined it is in compliance with applicable institutional and federal policies.</p> <p>The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.</p> <p>The Primary Reviewer made a motion to approve this submission.</p> <p>The Committee unanimously supported the motion.</p>

Administratively-Approved Exempt Registrations and Amendments

Continuing Review for BIO20220111

Continuing Review

Principal Investigator	Stephen Adam
Submission ID	BIO20220111-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-D-1• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	5/30/2025

Amendment for BIO20240007

Amendment

Principal Investigator	Miriam Bornhorst
Submission ID	BIO20240007-AM0003
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D• Section III-F-8
Containment Level	BSL-2
Approval Date	6/2/2025

Amendment for BIO20220053

Amendment

Principal Investigator	Thomas Bozza
Submission ID	BIO20220053-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D-2• Section III-D• Section III-F-8
Containment Level	BSL-2
Approval Date	5/30/2025

Continuing Review for BIO20220068**Continuing Review**

Principal Investigator	Paul Burridge
Submission ID	BIO20220068-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	5/22/2025

Amendment for BIO20230085**Amendment**

Principal Investigator	Mercedes Carnethon
Submission ID	BIO20230085-AM0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	5/20/2025

Continuing Review for BIO20220093**Continuing Review**

Principal Investigator	Anis Contractor
Submission ID	BIO20220093-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-b• Section III-D-4-a• Section III-D-4• Section III-F• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D• Section III-D-4-c• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/2/2025

Continuing Review for BIO20230105**Continuing Review**

Principal Investigator	Andrea Domenighetti
Submission ID	BIO20230105-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-F-8
Containment Level	BSL-2
Approval Date	5/28/2025

Continuing Review for BIO20240057**Continuing Review**

Principal Investigator	Elizabeth Eklund
Submission ID	BIO20240057-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F-1• Section III-D-1• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	5/23/2025

Ellis Lab**Initial Protocol**

Principal Investigator	Michael Ellis
Submission ID	BIO20250080
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	5/30/2025

Espinosa Lab**Initial Protocol**

Principal Investigator	Horacio Espinosa
Submission ID	BIO20250070
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Approval Date	5/14/2025

Continuing Review for BIO20220109**Continuing Review**

Principal Investigator	Daniel Richard Foltz
Submission ID	BIO20220109-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-1-a• Section III-F• Section III-E• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-D-2• Section III-D• Section III-D-3• Section III-D-3-a• Section III-F-8
Containment Level	BSL-2
Approval Date	6/12/2025

Continuing Review for BIO20220125**Continuing Review**

Principal Investigator	Ruli Gao
Submission ID	BIO20220125-CR0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	6/2/2025

Continuing Review for BIO20230117**Continuing Review**

Principal Investigator	Tamar Devora Gefen
Submission ID	BIO20230117-CR0002
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	6/13/2025

Continuing Review for BIO20220108**Continuing Review**

Principal Investigator	Changiz Geula
Submission ID	BIO20220108-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-F• Section III-E• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Approval Date	5/19/2025

Continuing Review for BIO20230116**Continuing Review**

Principal Investigator	Songi Han
Submission ID	BIO20230116-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E
Containment Level	BSL-1
Approval Date	6/11/2025

Continuing Review for BIO20230088**Continuing Review**

Principal Investigator	Joyce Ho
Submission ID	BIO20230088-CR0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	BSL-2
Approval Date	6/17/2025

Amendment for BIO20220042**Amendment**

Principal Investigator	John Kessler
Submission ID	BIO20220042-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-E-3-a• Section III-D-4• Section III-D-4-c-(1)• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D-4-c-(2)• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/5/2025

Continuing Review for BIO20220048**Continuing Review**

Principal Investigator	Joseph Leventhal
Submission ID	BIO20220048-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1
Containment Level	BSL-2
Approval Date	6/11/2025

Continuing Review for BIO20230098**Continuing Review**

Principal Investigator	Loretta Li
Submission ID	BIO20230098-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4• Section III-F• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-2• Section III-D-3• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2+
Approval Date	5/28/2025

Continuing Review for BIO20230089**Continuing Review**

Principal Investigator	Yaping Liu
Submission ID	BIO20230089-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Approval Date	6/2/2025

Continuing Review for BIO20220102**Continuing Review**

Principal Investigator	Styliani Markoulaki
Submission ID	BIO20220102-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-F• Section III-E• Section III-F-1• Section III-D-2• Section III-D
Containment Level	BSL-2
Approval Date	5/28/2025

Continuing Review for BIO20230025**Continuing Review**

Principal Investigator	Joe Mazzulli
Submission ID	BIO20230025-CR1
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-a• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D-4-c-(2)• Section III-D-2• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/11/2025

Continuing Review for BIO20230113**Continuing Review**

Principal Investigator	Elizabeth McNally
Submission ID	BIO20230113-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4-a• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/11/2025

Continuing Review for BIO20230086**Continuing Review**

Principal Investigator	Pamela Monahan
Submission ID	BIO20230086-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1
Containment Level	BSL-2
Approval Date	6/17/2025

Amendment for BIO20240043**Amendment**

Principal Investigator	Luisa Morales-Nebreda
Submission ID	BIO20240043-AM0004
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-7• Section III-D-4• Section III-F-1• Section III-F-8
Containment Level	BSL-2+
Approval Date	5/19/2025

Amendment for BIO20240043**Amendment**

Principal Investigator	Luisa Morales-Nebreda
Submission ID	BIO20240043-AM0005
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-7• Section III-D-4• Section III-F-1• Section III-F-8
Containment Level	BSL-2+
Approval Date	5/30/2025

Continuing Review for BIO20230057**Continuing Review**

Principal Investigator	Han Peng
Submission ID	BIO20230057-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-a• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-D-3• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/10/2025

Continuing Review for BIO20220157**Continuing Review**

Principal Investigator	Bethany Perez White
Submission ID	BIO20220157-CR0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/11/2025

Continuing Review for BIO20230003**Continuing Review**

Principal Investigator	Harris Perlman
Submission ID	BIO20230003-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-E-3-a• Section III-D-4-c-(1)• Section III-F• Section III-E• Section III-F-8-C-VII• Section III-D• Section III-F-8-C-VIII
Containment Level	BSL-2
Approval Date	5/15/2025

Amendment for BIO20230104**Amendment**

Principal Investigator	Brian Popko
Submission ID	BIO20230104-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F-2• Section III-D-4-a• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/6/2025

Continuing Review for BIO20230104**Continuing Review**

Principal Investigator	Brian Popko
Submission ID	BIO20230104-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F-2• Section III-D-4-a• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	5/23/2025

Amendment/CR for BIO20220106**Amendment/CR**

Principal Investigator	Daniele Procissi
Submission ID	BIO20220106-AMCR0001
Applicable NIH Guidelines covering the entire registration	
Containment Level	N/A
Approval Date	3/31/2025

Amendment for BIO20240019**Amendment**

Principal Investigator	Jeffrey Savas
Submission ID	BIO20240019-AM0002
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-E-3• Section III-D-4• Section III-F• Section III-E• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D• Section III-D-3• Section III-F-8-C-VIII• Section III-F-8
Containment Level	BSL-2
Approval Date	6/12/2025

Continuing Review for BIO20220012**Continuing Review**

Principal Investigator	Gregory Schwartz
Submission ID	BIO20220012-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-a• Section III-D-4• Section III-F• Section III-F-8-C-II• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D
Containment Level	BSL-2
Approval Date	6/4/2025

Amendment for BIO20240195**Amendment**

Principal Investigator	Arun Sharma
Submission ID	BIO20240195-AM0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-b• Section III-D-4-a• Section III-D-4• Section III-F• Section III-D-1• Section III-F-8-C-VII• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	5/20/2025

Continuing Review for BIO20220039**Continuing Review**

Principal Investigator	Vipul Shukla
Submission ID	BIO20220039-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-4-a• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D-4-c-(2)• Section III-D-2• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	6/12/2025

Continuing Review for BIO20240069**Continuing Review**

Principal Investigator	Xinkun Wang
Submission ID	BIO20240069-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-E• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Approval Date	6/17/2025

Continuing Review for BIO20240023**Continuing Review**

Principal Investigator	Lisa Wilsbacher
Submission ID	BIO20240023-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-F• Section III-F-1• Section III-F-8
Containment Level	BSL-2
Approval Date	5/28/2025

Continuing Review for BIO20220050**Continuing Review**

Principal Investigator	Zheng Zhang
Submission ID	BIO20220050-CR0001
Applicable NIH Guidelines covering the entire registration	<ul style="list-style-type: none">• Section III-D-1-a• Section III-E-3• Section III-E-3-a• Section III-D-4• Section III-F• Section III-E• Section III-F-1• Section III-D-1• Section III-F-8-C-VII• Section III-D• Section III-D-3• Section III-F-8
Containment Level	BSL-2
Approval Date	5/22/2025

Other Agenda Items